45.10
price up icon2.15%   0.95
after-market アフターアワーズ: 45.08 -0.02 -0.04%
loading
前日終値:
$44.15
開ける:
$44.18
24時間の取引高:
35.90M
Relative Volume:
2.77
時価総額:
$91.80B
収益:
$47.70B
当期純損益:
$5.07B
株価収益率:
18.19
EPS:
2.48
ネットキャッシュフロー:
$14.58B
1週間 パフォーマンス:
+0.42%
1か月 パフォーマンス:
-4.41%
6か月 パフォーマンス:
-26.05%
1年 パフォーマンス:
-12.83%
1日の値動き範囲:
Value
$44.12
$45.53
1週間の範囲:
Value
$43.19
$45.53
52週間の値動き範囲:
Value
$42.96
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
名前
Bristol Myers Squibb Co
Name
セクター
Healthcare (1147)
Name
電話
(609) 252-4621
Name
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
職員
34,100
Name
Twitter
@BMSNEWS
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
BMY's Discussions on Twitter

BMY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
45.10 89.86B 47.70B 5.07B 14.58B 2.48
Drug Manufacturers - General icon
LLY
Lilly Eli Co
763.00 651.28B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
185.42 437.40B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
231.54 394.23B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
128.24 240.24B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
83.93 196.28B 63.43B 16.42B 14.72B 6.49

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-08-05 ダウングレード Daiwa Securities Outperform → Neutral
2025-04-22 開始されました Cantor Fitzgerald Neutral
2025-04-22 開始されました Piper Sandler Overweight
2024-12-16 アップグレード Jefferies Hold → Buy
2024-12-10 再開されました BofA Securities Neutral
2024-11-15 開始されました Wolfe Research Peer Perform
2024-11-13 アップグレード Daiwa Securities Neutral → Outperform
2024-11-12 アップグレード Leerink Partners Market Perform → Outperform
2024-10-25 ダウングレード Citigroup Buy → Neutral
2024-10-17 開始されました Bernstein Mkt Perform
2024-07-29 ダウングレード Barclays Overweight → Equal Weight
2024-03-11 ダウングレード Societe Generale Buy → Hold
2024-02-06 ダウングレード Redburn Atlantic Buy → Neutral
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-11-15 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-11-09 開始されました Deutsche Bank Hold
2023-11-02 ダウングレード Daiwa Securities Outperform → Neutral
2023-10-27 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-10-27 アップグレード HSBC Securities Reduce → Hold
2023-10-27 ダウングレード William Blair Outperform → Mkt Perform
2023-10-20 再開されました UBS Neutral
2023-07-14 開始されました HSBC Securities Reduce
2023-07-10 開始されました SVB Securities Market Perform
2023-06-28 開始されました Daiwa Securities Outperform
2023-03-06 開始されました Jefferies Hold
2023-01-17 開始されました Cantor Fitzgerald Overweight
2022-11-18 開始されました Credit Suisse Neutral
2022-10-10 ダウングレード Guggenheim Buy → Neutral
2022-09-14 ダウングレード Berenberg Buy → Hold
2022-06-03 ダウングレード Raymond James Outperform → Mkt Perform
2022-04-06 再開されました Morgan Stanley Underweight
2021-12-17 開始されました Goldman Buy
2021-12-09 再開されました Wells Fargo Equal Weight
2021-11-19 開始されました BMO Capital Markets Outperform
2021-11-01 ダウングレード Argus Buy → Hold
2021-07-27 再開されました Truist Buy
2021-04-30 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-04-13 アップグレード Truist Hold → Buy
2020-11-16 アップグレード Societe Generale Hold → Buy
2020-11-10 再開されました Bernstein Mkt Perform
2020-11-06 ダウングレード Gabelli & Co Buy → Hold
2020-10-19 アップグレード Guggenheim Neutral → Buy
2020-09-29 開始されました Berenberg Buy
2020-07-28 開始されました Raymond James Outperform
2020-04-02 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-23 ダウングレード Societe Generale Buy → Hold
2020-02-27 開始されました Barclays Equal Weight
2020-01-06 再開されました Citigroup Buy
2019-12-13 アップグレード Argus Hold → Buy
2019-11-22 再開されました Morgan Stanley Equal-Weight
2019-10-17 再開されました BofA/Merrill Buy
2019-08-14 アップグレード Atlantic Equities Neutral → Overweight
2019-05-28 開始されました Goldman Buy
2019-05-20 ダウングレード Argus Buy → Hold
2019-05-03 アップグレード Barclays Equal Weight → Overweight
2019-05-03 再開されました JP Morgan Overweight
2019-01-15 アップグレード Societe Generale Sell → Buy
2018-10-22 ダウングレード Citigroup Buy → Neutral
すべてを表示

Bristol Myers Squibb Co (BMY) 最新ニュース

pulisher
07:28 AM

Judge denies motions by Bristol-Myers Squibb, State Street IM to dismiss PRT lawsuit - Pensions & Investments

07:28 AM
pulisher
01:28 AM

Bristol Myers Squibb call volume above normal and directionally bullish - TipRanks

01:28 AM
pulisher
11:00 AM

Multiple Modalities in the Oncology Market Size, Regional Growth and Trends - GlobeNewswire Inc.

11:00 AM
pulisher
09:27 AM

Bristol-Myers Retirees’ Pension De-Risking Suit Moves Forward - Bloomberg Law News

09:27 AM
pulisher
06:09 AM

Bristol Myers Squibb Company $BMY Position Cut by Capital Investment Advisors LLC - MarketBeat

06:09 AM
pulisher
Sep 29, 2025

JLL: Bristol Myers Squibb eyes sale, partial leaseback of 1.2 million sq. ft. Summit campus - Real Estate NJ

Sep 29, 2025
pulisher
Sep 29, 2025

Bristol-Myers Squibb Company (BMY) Stock Analysis: 20% Upside Potential Amid Strong Dividend Yield - DirectorsTalk Interviews

Sep 29, 2025
pulisher
Sep 28, 2025

Fort Washington Investment Advisors Inc. OH Acquires 7,095 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

Sep 28, 2025
pulisher
Sep 28, 2025

KG&L Capital Management LLC Buys 39,136 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

Sep 28, 2025
pulisher
Sep 27, 2025

Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios - Insider Monkey

Sep 27, 2025
pulisher
Sep 27, 2025

State of Alaska Department of Revenue Trims Stake in Bristol Myers Squibb Company $BMY - MarketBeat

Sep 27, 2025
pulisher
Sep 27, 2025

Bristol Myers Squibb Company $BMY Position Trimmed by TD Private Client Wealth LLC - MarketBeat

Sep 27, 2025
pulisher
Sep 26, 2025

Trump's Drug Tariffs 'A Meaningful Commercial Hit' For Americans, Says AnalystEli Lilly (NYSE:LLY), Bristol-Myers Squibb (NYSE:BMY) - Benzinga

Sep 26, 2025
pulisher
Sep 26, 2025

Bristol Myers Squibb discovers new TLR7 agonists - BioWorld MedTech

Sep 26, 2025
pulisher
Sep 26, 2025

BMS adds discounted psoriasis drug to its DTC channel - pharmaphorum

Sep 26, 2025
pulisher
Sep 26, 2025

Meyer Handelman Co. Has $24.44 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat

Sep 26, 2025
pulisher
Sep 25, 2025

BMS Expands Patient Options With Direct-to-Patient Platform - Dermatology Times

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers Squibb to Offer More Than 80% off Sotyktu List Price - Managed Healthcare Executive

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers Squibb leans into direct-to-consumer with telehealth launch, drug price drop - eMarketer

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026 - Stocktwits

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers to sell psoriasis drug at over 80% discount to some US patients - Reuters

Sep 25, 2025
pulisher
Sep 25, 2025

BMS expands DTC offering with Sotyktu addition - Pharmaceutical Technology

Sep 25, 2025
pulisher
Sep 25, 2025

PGIM Jennison Health Sciences Fund Sold its Position in Bristol-Myers Squibb Co. (BMY) in Q2 - Insider Monkey

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers Squibb (BMY) Expands Discounted Drug Offerings - GuruFocus

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers (BMY) Expands Direct Patient Access to Key Medicat - GuruFocus

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers expands DTC offerings (BMY:NYSE) - Seeking Alpha

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol to Sell 80% Off Psoriasis Pill After Trump Demand - Bloomberg.com

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers Squibb to offer steep discounts on Eliquis and Sotyktu - Investing.com Canada

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib) - TradingView

Sep 25, 2025
pulisher
Sep 25, 2025

80% Price Cut: Bristol Myers Squibb Makes Breakthrough Psoriasis Drug Sotyktu More Accessible - Stock Titan

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol Myers (BMY) Advances in Pulmonary Fibrosis Treatment - GuruFocus

Sep 25, 2025
pulisher
Sep 25, 2025

Bristol to Sell Psoriasis Pill for 80% Off After Trump Demand - Bloomberg.com

Sep 25, 2025
pulisher
Sep 24, 2025

FDA issues complete response letter for Bristol-Myers Squibb's hepatitis C drug daclatasvir - FirstWord Pharma

Sep 24, 2025
pulisher
Sep 24, 2025

Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance

Sep 24, 2025
pulisher
Sep 24, 2025

Bristol-Myers Squibb's Opdivo superior to chemotherapy in Phase III trial in advanced melanoma - FirstWord Pharma

Sep 24, 2025
pulisher
Sep 24, 2025

Bristol-Myers Squibb (BMY) Faces Extended Losses Amid Analyst Op - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Pharma Is Pushing $200,000 Cancer Drugs When Cheaper Doses May Work - Bloomberg.com

Sep 24, 2025
pulisher
Sep 24, 2025

BMS Phase III success with iberdomide - The Pharma Letter

Sep 24, 2025
pulisher
Sep 24, 2025

BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study - Yahoo Finance

Sep 24, 2025
pulisher
Sep 24, 2025

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients - Sahm

Sep 24, 2025
pulisher
Sep 24, 2025

BMS eyes filings for myeloma 'celmod' iberdomide - pharmaphorum

Sep 24, 2025
pulisher
Sep 24, 2025

When It Pays to Buy Stocks of Companies Clouded in Controversy - Morningstar

Sep 24, 2025
pulisher
Sep 24, 2025

Bristol Myers Squibb’s new multiple myeloma therapy shows promise By Investing.com - Investing.com Nigeria

Sep 24, 2025
pulisher
Sep 24, 2025

CHICAGO TRUST Co NA Sells 10,191 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Become a business supplier - Bristol Myers Squibb

Sep 24, 2025
pulisher
Sep 24, 2025

Bristol-Myers Squibb Is Facing a Patent Cliff, but a Solid Pipeline Supports a Wide Moat - Morningstar

Sep 24, 2025
pulisher
Sep 23, 2025

Bristol Myers Squibb Company $BMY Shares Sold by UMB Bank n.a. - MarketBeat

Sep 23, 2025
pulisher
Sep 23, 2025

Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment - Yahoo Finance

Sep 23, 2025
pulisher
Sep 23, 2025

Bristol Myers’ US/UK List Price Parity Plan For Cobenfy Leverages Trump’s MFN Concerns - insights.citeline.com

Sep 23, 2025
pulisher
Sep 23, 2025

BMS’s Iberdomide Scores First Major Phase III Win - insights.citeline.com

Sep 23, 2025
pulisher
Sep 23, 2025

Diversified Trust Co Purchases 9,105 Shares of Bristol Myers Squibb Company $BMY - MarketBeat

Sep 23, 2025

Bristol Myers Squibb Co (BMY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$47.20
price up icon 3.40%
$111.00
price down icon 1.44%
drug_manufacturers_general PFE
$25.48
price up icon 6.83%
$282.20
price up icon 3.00%
drug_manufacturers_general NVO
$55.49
price down icon 0.02%
drug_manufacturers_general MRK
$83.93
price up icon 6.81%
大文字化:     |  ボリューム (24 時間):